Karyopharm Therapeutics Inc.

quarter and full year 2023 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Ellen Webb, Senior Vice President of Investor Relations. Please go ahead.

Thank you, Ludi, and thank you all for joining us on today's conference call to discuss our financial results and recent company progress. We issued a press release this morning detailing our financial results for the fourth quarter and full year 2023. This release, along with a slide presentation that we will reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Rejma, Sohania, and Mike, who will provide an update on our results for the fourth quarter and full year 2023 and recent clinical developments. Before we begin our formal comments, I'll remind you that various remarks we'll make today constitute forward-looking statements, FLS, for purposes of the safe harbor provision under the Private Securities Dedication Reform Act of 1995 as outlined on slide three. Actual results may differ materially from those indicated by these FLS as a result of various important factors. including those discussed in the risk factors section of our most recent form 10Q or 10K, which are on file with the SEC, and in other filings that we may make with the SEC in the future. Any FLS represents our views as of today only. While we may elect to update these FLS at some point in the future, we specifically do claim any obligation to do so, even if our views change. Therefore, you should now rely on these SLS as representing our views as of any later date. I will now turn the call over to Richard. Please turn to slide four.

Good morning.